GLP-1 drugs are indicated for patients with BMI above 25 even without complications, or BMI above 23 with obesity-related conditions such as diabetes, hypertension, or fatty liver disease
Using them without proper medical guidancethrough overseas orders, self-direction, or telehealth with little follow-upcan be risky
You might notice: I often encourage clients to explore what new cues might show up
With an effective oral GLP1 on the horizon, we may be entering the next phase of diabetes care,one that could expand access while reshaping treatment pathways
In the OASIS 4 trial, the largest Phase 3 study of oral semaglutide for weight management, adults taking the 25mg tablet lost an average of 13.6% of their starting body weight over 64 weeks, compared with just 2.2% in the placebo group
Dietary supplementation with 1% and 2% glycine to Phase-I HSB increased concentrations of guanidinoacetate and creatine in the kidneys in a dose-dependent manner (Table 1)